Mylan appeals ATO’s rejection of $48M deduction in spat over $1.2B Alphapharm deal

ATO 2022-09-19 2:04 pm By Cat Fredenburgh

Please login to bookmark

The Australian unit of Mylan is challenging the ATO’s rejection of a $48 million deduction for 2020 in the generic drug company’s latest spat with the tax office over interest on loans to fund its $1.2 billion acquisition of generic drug maker Alphapharm.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au